Skip to main content
Erschienen in: Cancer Causes & Control 7/2006

01.09.2006 | Original Paper

Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States)

verfasst von: Jihyoun Jeon, E. Georg Luebeck, Suresh H. Moolgavkar

Erschienen in: Cancer Causes & Control | Ausgabe 7/2006

Einloggen, um Zugang zu erhalten

Abstract

A number of hypotheses have been advanced to explain the rapid increase of the incidence of esophageal adenocarcinoma in the US. A major problem in identifying and understanding the nature of this increase is the difficulty in untangling age effects from temporal trends due to cohort and period effects. To address this problem, we have developed multi-stage carcinogenesis models that describe the age-specific incidence of adenocarcinoma of the esophagus and of the gastric cardia with separate adjustments for temporal trends. These models explicitly incorporate important features of the cancers, such as the metaplastic conversion of normal esophagus to Barrett’s esophagus (BE). We fit these models separately to the incidence of adenocarcinoma of the esophagus and of the gastric cardia reported in the Surveillance Epidemiology and End Results (SEER) registry over the period 1973–2000. We conclude that the incidence of both cancers is consistent with a sequence that posits a tissue conversion step in the target organ followed by a multi-stage process with three rate-limiting events, the first two leading to an initiated cell that can expand clonally into a premalignant lesion, and the third converting an initiated cell into a malignant cell. Temporal trends in the incidence of both cancers are dominated by dramatically increasing period effects.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
C. Maley, personal communication.
 
2
BRFSS: Behavioral Risk Factor Surveillance System, 1990–2000 Prevalence of Obesity Among U.S. Adults by state (BRFSS (1990–2000); self-reported data). Internet address: http://​www.​cdc.​gov/​nccdphp/​dnpa/​obesity/​trend/​prev_​reg.​htm.
 
3
T.L. Vaughan, personal communication.
 
Literatur
1.
Zurück zum Zitat Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92:549–555PubMedCrossRef Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92:549–555PubMedCrossRef
2.
Zurück zum Zitat Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654PubMedCrossRef Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654PubMedCrossRef
3.
Zurück zum Zitat Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053PubMedCrossRef Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053PubMedCrossRef
4.
Zurück zum Zitat El-Serag HB, Mason AC, Petersen N, Key CR (2002) Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 50:368–372PubMedCrossRef El-Serag HB, Mason AC, Petersen N, Key CR (2002) Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 50:368–372PubMedCrossRef
5.
Zurück zum Zitat Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627–1633PubMed Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627–1633PubMed
6.
Zurück zum Zitat Nguyen AM, Luke CG, Roder D (2003) Comparative epidemiological characteristics of oesophageal adenocarcinoma and other cancers of the oesophagus and gastric cardia. Asian Pac J Cancer Prev 4:225–231PubMed Nguyen AM, Luke CG, Roder D (2003) Comparative epidemiological characteristics of oesophageal adenocarcinoma and other cancers of the oesophagus and gastric cardia. Asian Pac J Cancer Prev 4:225–231PubMed
7.
Zurück zum Zitat Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868PubMedCrossRef Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868PubMedCrossRef
8.
Zurück zum Zitat Younes M, Henson DE, Ertan A, Miller CC (2002) Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 37:1359–1365PubMedCrossRef Younes M, Henson DE, Ertan A, Miller CC (2002) Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 37:1359–1365PubMedCrossRef
9.
Zurück zum Zitat Vaughan TL (2002) Esophagus. In: Franco EL, Rohan TE (eds) Cancer precursors. Springer-Verlag New York, Inc., pp 69–116 Vaughan TL (2002) Esophagus. In: Franco EL, Rohan TE (eds) Cancer precursors. Springer-Verlag New York, Inc., pp 69–116
11.
Zurück zum Zitat Kim R, Weissfeld JL, Reynolds JC, Kuller LH (1997) Etiology of Barrett’s metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 6:369–377PubMed Kim R, Weissfeld JL, Reynolds JC, Kuller LH (1997) Etiology of Barrett’s metaplasia and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 6:369–377PubMed
12.
Zurück zum Zitat Ramel S (2003) Barrett’s esophagus:model of neoplastic progression. World J Surg 27:1009–1013PubMedCrossRef Ramel S (2003) Barrett’s esophagus:model of neoplastic progression. World J Surg 27:1009–1013PubMedCrossRef
13.
Zurück zum Zitat Reid BJ (1991) Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin N Am 20:817–834 Reid BJ (1991) Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin N Am 20:817–834
14.
Zurück zum Zitat Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA 287:1972–1981PubMedCrossRef Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA 287:1972–1981PubMedCrossRef
15.
Zurück zum Zitat Vaughan TL, Kristal AR, Blount PL, et al (2002) Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 11:745–752PubMed Vaughan TL, Kristal AR, Blount PL, et al (2002) Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 11:745–752PubMed
16.
Zurück zum Zitat Whittles CE, Biddlestone LR, Burton A, et al (1999) Apoptotic and proliferative activity in the neoplastic progression of Barrett’s oesophagus:a comparative study. J Pathol 187:535–540PubMedCrossRef Whittles CE, Biddlestone LR, Burton A, et al (1999) Apoptotic and proliferative activity in the neoplastic progression of Barrett’s oesophagus:a comparative study. J Pathol 187:535–540PubMedCrossRef
17.
Zurück zum Zitat Wild CP, Hardie LJ (2003) Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3:676–684PubMedCrossRef Wild CP, Hardie LJ (2003) Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3:676–684PubMedCrossRef
18.
Zurück zum Zitat Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA (1990) Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99:918–922PubMed Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA (1990) Prevalence of columnar-lined (Barrett’s) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 99:918–922PubMed
19.
Zurück zum Zitat Wang LD, Zheng S, Zheng ZY, Casson AG (2003) Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol 9:1156–1164PubMed Wang LD, Zheng S, Zheng ZY, Casson AG (2003) Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. World J Gastroenterol 9:1156–1164PubMed
20.
Zurück zum Zitat Powell J, McConkey CC, Gillison EW, Spychal RT (2002) Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 102:422–427PubMedCrossRef Powell J, McConkey CC, Gillison EW, Spychal RT (2002) Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 102:422–427PubMedCrossRef
21.
Zurück zum Zitat Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW (1999) Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 86:529–535PubMedCrossRef Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW (1999) Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 86:529–535PubMedCrossRef
22.
Zurück zum Zitat Corley DA, Buffler PA (2001) Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 30:1415–1425PubMedCrossRef Corley DA, Buffler PA (2001) Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the cancer incidence in five continents database. Int J Epidemiol 30:1415–1425PubMedCrossRef
23.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database:Incidence – SEER Regs Public-Use, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission Surveillance, Epidemiology, and End Results (SEER) Program (http://​www.​seer.​cancer.​gov) SEER*Stat Database:Incidence – SEER Regs Public-Use, Nov 2002 Sub (1973–2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission
24.
Zurück zum Zitat Holford TR (1991) Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 12:425–457PubMedCrossRef Holford TR (1991) Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 12:425–457PubMedCrossRef
25.
Zurück zum Zitat Kupper LL, Janis JM, Karmous A, Greenberg BG (1985) Statistical age–period–cohort analysis: a review and critique. J Chronic Dis 38:811–830PubMedCrossRef Kupper LL, Janis JM, Karmous A, Greenberg BG (1985) Statistical age–period–cohort analysis: a review and critique. J Chronic Dis 38:811–830PubMedCrossRef
26.
Zurück zum Zitat Zheng T, Mayne ST, Holford TR, et al (1992) Time trend and age–period–cohort effects on incidence of esophageal cancer in Connecticut, 1935–89. Cancer Causes Control 3:481–492PubMedCrossRef Zheng T, Mayne ST, Holford TR, et al (1992) Time trend and age–period–cohort effects on incidence of esophageal cancer in Connecticut, 1935–89. Cancer Causes Control 3:481–492PubMedCrossRef
27.
Zurück zum Zitat Clayton D, Schifflers E (1987) Models for temporal variation in cancer rates. I: Age–period and age–cohort models. Stat Med 6:449–467PubMed Clayton D, Schifflers E (1987) Models for temporal variation in cancer rates. I: Age–period and age–cohort models. Stat Med 6:449–467PubMed
28.
Zurück zum Zitat Holford TR (1992) Analysing the temporal effects of age, period and cohort. Stat Methods Med Res 1:317–337PubMed Holford TR (1992) Analysing the temporal effects of age, period and cohort. Stat Methods Med Res 1:317–337PubMed
29.
Zurück zum Zitat Luebeck EG, Moolgavkar SH (2002) Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 99:15095–15100PubMedCrossRef Luebeck EG, Moolgavkar SH (2002) Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 99:15095–15100PubMedCrossRef
30.
Zurück zum Zitat Cameron AJ, Lomboy CT (1992) Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103:1241–1245PubMed Cameron AJ, Lomboy CT (1992) Barrett’s esophagus: age, prevalence, and extent of columnar epithelium. Gastroenterology 103:1241–1245PubMed
31.
Zurück zum Zitat Wong DJ, Paulson TG, Prevo LJ, et al (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res 61:8284–8289PubMed Wong DJ, Paulson TG, Prevo LJ, et al (2001) p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’s metaplastic epithelium. Cancer Res 61:8284–8289PubMed
32.
Zurück zum Zitat Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res 64:3414–3427PubMedCrossRef Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res 64:3414–3427PubMedCrossRef
33.
Zurück zum Zitat Heidenreich WF, Luebeck EG, Moolgavkar SH (1997) Some properties of the hazard function of the two-mutation clonal expansion model. Risk Anal 17:391–399PubMedCrossRef Heidenreich WF, Luebeck EG, Moolgavkar SH (1997) Some properties of the hazard function of the two-mutation clonal expansion model. Risk Anal 17:391–399PubMedCrossRef
34.
Zurück zum Zitat Mayne ST, Navarro SA (2002) Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 132:3467S–3470SPubMed Mayne ST, Navarro SA (2002) Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 132:3467S–3470SPubMed
35.
Zurück zum Zitat Haggitt RC (1994) Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982–993PubMedCrossRef Haggitt RC (1994) Barrett’s esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25:982–993PubMedCrossRef
36.
Zurück zum Zitat Herbst JJ, Berenson MM, McCloskey DW, Wiser WC (1978) Cell proliferation in esophageal columnar epithelium (Barrett’s esophagus). Gastroenterology 75:683–687PubMed Herbst JJ, Berenson MM, McCloskey DW, Wiser WC (1978) Cell proliferation in esophageal columnar epithelium (Barrett’s esophagus). Gastroenterology 75:683–687PubMed
37.
Zurück zum Zitat Uys P, van Helden PD (2003) On the nature of genetic changes required for the development of esophageal cancer. Mol Carcinog 36:82–89PubMedCrossRef Uys P, van Helden PD (2003) On the nature of genetic changes required for the development of esophageal cancer. Mol Carcinog 36:82–89PubMedCrossRef
38.
Zurück zum Zitat Maley CC, Galipeau PC, Li X, et al (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64:7629–7633PubMedCrossRef Maley CC, Galipeau PC, Li X, et al (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64:7629–7633PubMedCrossRef
39.
Zurück zum Zitat Cameron AJ, Arora AS (2002) Barrett’s esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol 97:273–278PubMedCrossRef Cameron AJ, Arora AS (2002) Barrett’s esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol 97:273–278PubMedCrossRef
40.
Zurück zum Zitat Farrow DC, Vaughan TL, Sweeney C et al (2000) Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11:231–238PubMedCrossRef Farrow DC, Vaughan TL, Sweeney C et al (2000) Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11:231–238PubMedCrossRef
41.
Zurück zum Zitat Cameron AJ (2002) Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus 15:106–108PubMedCrossRef Cameron AJ (2002) Epidemiology of Barrett’s esophagus and adenocarcinoma. Dis Esophagus 15:106–108PubMedCrossRef
42.
Zurück zum Zitat Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRef Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146PubMedCrossRef
43.
Zurück zum Zitat Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54(Suppl 1):1–5CrossRef Lagergren J (2005) Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 54(Suppl 1):1–5CrossRef
44.
Zurück zum Zitat Engel LS, Chow W, Vaughan TL, et al (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404–1413PubMed Engel LS, Chow W, Vaughan TL, et al (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404–1413PubMed
45.
Zurück zum Zitat Cameron AJ, Welborn TA, Zimmet PZ, et al (2003) Overweight and obesity in Australia:the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 178:427–432PubMed Cameron AJ, Welborn TA, Zimmet PZ, et al (2003) Overweight and obesity in Australia:the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust 178:427–432PubMed
46.
Zurück zum Zitat La Vecchia C, Negri E, Lagiou P, Trichopoulos D (2002) Oesophageal adenocarcinoma: a paradigm of mechanical carcinogenesis? Int J Cancer 102:269–270PubMedCrossRef La Vecchia C, Negri E, Lagiou P, Trichopoulos D (2002) Oesophageal adenocarcinoma: a paradigm of mechanical carcinogenesis? Int J Cancer 102:269–270PubMedCrossRef
47.
Zurück zum Zitat Barrett MT, Sanchez CA, Prevo LJ, et al (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22:106–109PubMedCrossRef Barrett MT, Sanchez CA, Prevo LJ, et al (1999) Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 22:106–109PubMedCrossRef
48.
Zurück zum Zitat Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res 64:3414–3427PubMedCrossRef Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ (2004) Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett’s esophagus. Cancer Res 64:3414–3427PubMedCrossRef
49.
Zurück zum Zitat Shaheen NJ, Inadomi JM, Overholt BF, Sharma P (2004) What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut 53:1736–1744PubMedCrossRef Shaheen NJ, Inadomi JM, Overholt BF, Sharma P (2004) What is the best management strategy for high grade dysplasia in Barrett’s oesophagus? A cost effectiveness analysis. Gut 53:1736–1744PubMedCrossRef
50.
Zurück zum Zitat Spechler SJ, Barr H (2004) Review article: screening and surveillance of Barrett’s oesophagus: what is a cost-effective framework? Aliment Pharmacol Ther 19(Suppl 1):49–53PubMedCrossRef Spechler SJ, Barr H (2004) Review article: screening and surveillance of Barrett’s oesophagus: what is a cost-effective framework? Aliment Pharmacol Ther 19(Suppl 1):49–53PubMedCrossRef
51.
Zurück zum Zitat Vaughan TL, Dong LM, Blount PL, et al (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol 6:945–952PubMedCrossRef Vaughan TL, Dong LM, Blount PL, et al (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study. Lancet Oncol 6:945–952PubMedCrossRef
Metadaten
Titel
Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States)
verfasst von
Jihyoun Jeon
E. Georg Luebeck
Suresh H. Moolgavkar
Publikationsdatum
01.09.2006
Verlag
Kluwer Academic Publishers
Erschienen in
Cancer Causes & Control / Ausgabe 7/2006
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-006-0037-3

Weitere Artikel der Ausgabe 7/2006

Cancer Causes & Control 7/2006 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.